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A B S T R A C T   
Dried blood spot samples (DBS) provide an alternative sample type to venous blood samples for antibody testing. 
DBS are used by NHS for diagnosing Hepatitis C and by Public Health England for large scale HIV and Hepatitis C 
serosurveillance; the applicability of DBS based approaches for SARS-CoV-2 antibody detection is uncertain. The 
study aimed to compare antibody detection in DBS eluates using the Roche Elecsys ® immunoassay with anti-
body detection in paired plasma samples, using the same assay. The study was in one Police and one Fire & 
Rescue facility in England; it comprised of 195 participants within a larger sample COVID-19 serodiagnostics 
study of keyworkers, EDSAB-HOME. Outcome measures were sensitivity and specificity of DBS (the index test) 
relative to plasma (the reference test), at an experimental cut-off; quality of DBS sample collected; estimates of 
relative sensitivity of DBS vs. plasma immunoassay in a larger population. 18/195 (9.2%) participants tested 
positive using plasma samples. DBS sample quality varied markedly by phlebotomist, and low sample volume 
significantly reduced immunoassay signals. Using an experimental cut-off, sensitivity and specificity of DBS were 
89.0% (95% CI 67.2, 96.9%) and 100.0% (95% CI 97.9, 100%) respectively compared with using plasma. The 
limit of detection for DBS is about 30 times higher than for plasma. DBS use for SARS-CoV-2 serology, though 
feasible, is insensitive relative to immunoassays on plasma. Sample quality impacts on assay performance. Al-
ternatives, including the collection of capillary blood samples, should be considered for screening programs.   
1. Introduction 
Testing for SARS-CoV-2 antibodies is important to understand how 
the infection has spread in the population. However, extensive popula-
tion testing is not feasible using the currently available, highly sensitive 
immunoassays, due to the need to take venous blood samples. As such, 
serosurveillance using home sampling is currently limited to the use of 
lateral flow immunoassays (LFIAs), which often have limited sensitivity 
[1–5]. 
Dried blood spot (DBS) samples provide an alternative sample type to 
venous blood samples for antibody testing, and have been used exten-
sively in screening for other viruses including Hepatitis B, Hepatitis C 
and HIV [6]. Recent studies have demonstrated the feasibility of using 
DBS for home blood collection for SARS-CoV-2 antibody screening, with 
or without virtual supervision [7] as well as in infants [8]. Small scale 
feasibility studies have evaluated DBS samples for SARS-CoV-2 antibody 
detection in high risk populations, using plate based enzyme immuno-
assays, with promising results [9–12]. Field studies indicate the DBS 
approach is likely to be acceptable [13]. 
Recently, laboratories, including those in the United Kingdom (UK)’s 
National Health Service (NHS), have put in place high-throughput im-
munoassays for SARS-CoV-2 antibodies, which have to date used venous 
blood samples [14]. However, when considering population screening 
or individual risk assessment using antibody tests, an approach offering 
the potential advantages of easy and safe collection [15] without the 
need for phlebotomy training and with the possibility for self-collection 
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of samples [16], stability of the sample at ambient temperature once 
dried [17] and simple transport to the testing laboratory exempt from 
UN 3373 transport regulations [18] would be attractive. The taking and 
transporting of DBS samples has proved successful in screening for other 
viruses [19], and combined with testing on high throughput automated 
instrumentation could allow wider access to SARS-CoV-2 serology. 
Here we describe a pilot study evaluating the potential for using DBS 
for SARS-CoV-2 antibody testing using the Roche Elecsys ® Anti-SARS- 
CoV-2 immunoassay. We chose this platform because it is widely 
available across the UK’s NHS, and has one of the best performance 
characteristics of existing assays, as evidenced by a large-scale study 
[20]. The protocol used is an adaptation of that currently used by the 
Public Health England (PHE) Manchester virology laboratory for 
high-throughput screening of Hepatitis C. 
2. Methods 
2.1. Participants studied 
Samples were collected from volunteers attending two study loca-
tions over 2 days (3rd and 4th June 2020): Site 1 - Lancashire Police 
Headquarters and Site 2 - Lancashire Fire and Rescue Service. This 
recruitment was part of a larger ethically-approved study of UK key 
workers, Evaluating Detection of SARS-CoV-2 AntiBodies at HOME 
(EDSAB-HOME); full recruitment methods have been described [1,21]. 
In brief, volunteers were key workers who had been working on site 
during the pandemic, and who were neither experiencing any COVID-19 
compatible symptoms, currently or within the former seven days. 
Eligibility was unaffected by any prior COVID-19 compatible symptoms 
or SARS-CoV-2 nasal and throat swabs, or antibody tests. The overall 
approach, details of ethical approvals, and analysis are pre-specified in 
the study protocol available at http://www.isrctn.com/ISRCT 
N56609224. 
All EDSAB-HOME participants consented to provide a venous blood 
sample. All of those who attended a study clinic at Site 1 or 2 on the 3rd 
or 4th June were asked whether they would like to provide an additional 
DBS sample (this pilot study was ethically approved within the larger 
EDSAB-HOME protocol); as such, they form a convenience sample. 
Sample collection was performed by 7 different phlebotomists, 5 at Site 
1 and 2 at Site 2. The phlebotomists were experienced in the collection 
of venous blood samples but had no prior training in the collection of 
DBS samples, and a short on-site training session was provided. 
2.2. Ethical statement 
The EDSAB-HOME study was approved by NHS Research Ethics 
Committee (Health Research Authority, IRAS 284980) on 02/06/2020 
and PHE Research Ethics and Governance Group (REGG, NR0198) on 
21/05/2020. 
2.3. DBS collection system 
High flow BD Microtainer® lancets were used for puncturing 
fingertip skin. We aimed to collect 4 full size spots onto a custom 
designed collection card. The card comprised PerkinElmer 226 grade 
collection paper and circle outlines for the collection of 5 separate 25 μL 
blood spots, 4 of which are on a strip of paper attached with a perforated 
edge (Fig. 2) to enable removal using a disposable set of tweezers. 
Samples were stored at room temperature in ziplock bags containing a 
dessicant pack, and transported to PHE Manchester virology laboratory 
overnight. Samples were processed for elution on the 11th and 12th June, 
and stored at − 80 ◦C until tested on 18th June when reagents and ma-
chine time were available. 
This process is currently in use for analysis of Hepatitis C and HIV 
antibodies. Validation has been performed for antisera against both 
these agents showing that elution from dried blood and subsequent 
storage at − 80 ◦C for up to 2 weeks has minimal impact on immunoassay 
titres relative to immediate analysis, however we did not perform this 
validation for SARS-CoV-2 antibodies prior to this pilot study. 
2.4. Venous blood analysis (reference test) 
Venous blood samples were collected in 6 ml volumes in EDTA 
Vacutainer® tubes (Beckton Dickinson) at the same time as collection of 
DBS samples and were sent to the PHE Seroepidemiology unit (SEU) 
Manchester at the end of each day (3rd and 4th June) at room temper-
ature. Plasma samples were separated the following morning from the 
EDTA blood after centrifugation at 1200 g for 15 minutes, and stored at 
− 80 ◦C until sending to the PHE Rare and Imported Pathogens Labora-
tory (RIPL) Porton Down for testing (in ambient conditions overnight). 
All plasma samples were tested with the Roche Elecsys ® Anti-SARS- 
CoV-2 immunoassay run on the Roche cobas e 801 analytical unit, 
following the manufacturer’s instructions (COI ≥ 1.0 was considered 
positive). The Roche Elecsys ® Anti-SARS-CoV-2 immunoassay uses a 
recombinant protein representing the nucleocapsid (N) antigen and 
provides detection of antibodies (including IgG) and is validated for use 
on human serum and plasma. Results from the venous blood analysis 
were treated as the reference standard in this study and was chosen as 
this assay was the most sensitive and specific approach available for 
SARS-CoV-2 serological testing at PHE [20]. Samples were sent from the 
PHE SEU in Manchester on 17th June 2020; due to limited availability of 
the Roche machines, plasma samples were analysed at PHE, RIPL, Por-
ton Down between 29th June and 3rd July (as part of a large batch of 
EDSAB-HOME study samples). Between receipt and analysis, all plasma 
samples were stored at 4 ◦C. 
2.5. Dried blood spot analysis (index test) 
The size of the 4 spots collected on the card were assessed and 
recorded. A full-size spot filling the entire collection circle represents a 
DBS spot of 25 μl in size. Samples were rated as “good” if 4 full size spots 
were collected on the card, see Fig. 2a. Spots were considered “small” if 
on visual inspection one or more appeared to fill only 50% or more of the 
collection area, and “very small” if one or more appeared to fill less than 
50%, see Fig. 2b. A paper strip containing the 4 blood spots, the edges of 
which are pre-perforated, was removed using single use sterile forceps 
and placed in a 50 ml skirted centrifuge tube (Eppendorff) containing 
1 mL of PBS/Tween 0.05% (Sigma) elution buffer. Tubes were placed 
flat on an orbital shaker for overnight elution at room temperature. 
Eluates were aspirated and transferred to false bottom tubes (Roche 
Diagnostics) and 12 μL tested with the Roche Elecsys ® Anti-SARS-CoV- 
2 immunoassay run on the Roche e801 analyzer. Apart from using eluate 
instead of plasma, the protocol followed was that recommended by the 
manufacturer. Removal of the strip is a rapid step (~30 seconds) and the 
whole process takes about 1 minute hands-on per sample. 
Index tests were performed before the reference tests; those per-
forming the index tests were blind to the reference test results, and vice 
versa. No clinical information on the samples was available to those 
performing either the index or reference test. 
2.6. Statistical Analysis 
We described the quality of DBS samples overall, and by each indi-
vidual phlebotomist. Quantitative results from index and reference as-
says were depicted graphically. Among cases positive on the reference 
test, linear models were fitted using the R glm function modelling 
log10(y) ~ log10(x) + c + error, where y is the Roche Elecsys ® immu-
noassay signal in the DBS eluate, x is the Roche Elecsys ® immunoassay 
signal in the paired plasma sample, and c is a categorical variable rep-
resenting spot size, which is either 0 (if the spot size is ‘good’) vs. 1 if it is 
small or very small. 
For the index test, we derived an experimental cut-off, which is ten 
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median absolute deviations about the median in samples negative by the 
reference test. An estimated limit of detection was computed from the 
regression model above as the most likely reference test value at which 
the index test values were at the experimental cut-off. 
Sensitivity and specificity were computed by comparing the results 
of the dichotomised index test, using the experimental cut-off, relative to 
the dichotomised reference test result, using the manufacturer’s cut-off. 
All computations used R version 4.02. Receiver operating characteristic 
(ROC) analysis was performed using the pROC[22] package, linear 
modelling used the glm function, and confidence intervals around pro-
portions were computed using Wilson’s method with the Hmisc package 
binconf function. 
In a separate analysis, we examined the distribution of the reference 
test (Roche Elecsys ® immunoassay on plasma) in 2,652 samples from 
the EDSAB-HOME study, computing the immunoassay cumulative fre-
quency distribution, and comparing it with the predicted limit of 
detection of DBS samples. 
3. Results 
3.1. Participants 
We planned to recruit 200 individuals with paired venous and DBS 
samples from participants on 3rd and 4th June 2020. Of the 475 in-
dividuals attending EDSAB-HOME study on those dates, 195 samples 
were collected, of which 18 were positive using the reference assay 
(Fig. 1); 4 of the individuals reported having previously had a positive 
PCR test, while the remaining had not. Reasons for not collecting sam-
ples included subject or phlebotomist electing not to do so (which was 
permitted under the protocol). The demographics of those providing 
DBS samples were similar to those who did not from the same sample 
days (Table 1) and the larger EDSAB-HOME study cohort in Police & Fire 
Stream (Supplementary Table 1). 
3.2. Quality of DBS samples 
Overall, around two thirds of the DBS samples were rated as “good” 
(n = 121, 62.1%); 42 (21.6%) were “small” and 32 (16.3%) were “very 
small” (Fig. 2). The quality of sample collected varied by phlebotomist 
collecting the samples (Fig. 3) ranging from 26/27 samples rates as 
“good” size (Phlebotomist 7) to 0/21 rated as a “good” size (Phleboto-
mist 4). 
3.3. Accuracy of the test applied to DBS samples relative to plasma 
samples 
When we applied the manufacturer’s cutoff value, optimised for 
plasma, to the DBS eluates, the sensitivity relative to plasma was poor 
(44%, 95% CI 24.5, 66.2) (Table 2). We therefore considered whether 
the cutoff used for plasma was appropriate for our DBS eluates. 
The relationship between the immunoassay ratio from venous 
plasma vs. DBS is shown for the 195 samples in Fig. 4A. Although 
samples with negative reference tests gave very similar immunoassay 
ratios in both index and reference tests (black dots), positive samples 
generated lower results (median 0.7 vs. 18 units). However, for every 
unit increase in immunoassay signal in the Roche immunoassay per-
formed on plasma (the reference test), the immunoassay signal 
increased linearly provided the results were above the limit of detection 
(Fig. 4A). Linear modelling quantified both the relationship between the 
immunoassays signals in the two tests (the slope of the line in Fig. 4A) 
and the limit of detection (Table 4). The limit of detection of the 
immunoassay performed on DBS test was estimated as corresponding to 
5.9 antibody index units in tests on plasma (Fig. 4A). If we compute a 
limit of detection for the immunoassay on plasma in the same way we 
computed it for the immunoassay on DBS eluates, the cutoff is about 
0.17, or about 33 fold lower. This limit of detection, derived from a 
regression model is based on “good” quality spots. Since index test ratios 
were 45% (95% CI 23, 82%) smaller in those with smaller spots vs. the 
62% of “good” spots (Table 4), the test will be even less sensitive if 
smaller spots are obtained. 
Nevertheless, in this data set, the high correlation between tests re-
sults (Fig. 4A), the small number of test results with low reference test 
results, and a predominance of “good” size spots, generates a high area- 
under-curve in ROC analysis (c = 0.985, Fig. 4B). Using the experi-
mental cut-off derived above, of 18 positive samples using the reference 
test, 16 were positive in the index test giving a sensitivity estimate of 
Fig. 1. Flow diagram. 
Figure 1 Flow diagram illustrating where DBS samples were taken within the EDSAB-HOME study. 
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89.0% (95% CI 67.2, 96.9%), while maintaining a specificity of 100% 
(95% CI 97.9, 100%) (Table 2). Demographics and clinical symptoms of 
those testing positive on both the index test and reference test can be 
found in Table 3. 
To understand whether this sensitivity is likely to be applicable to 
other samples, we examined the reference test (Roche Elecsys ® 
immunoassay on plasma) in 2,652 samples from the EDSAB-HOME 
study (Fig. 1); there is no overlap between these samples and those on 
whom DBS samples were taken. Of these, 595 (22%) were positive on 
the reference assay, of which 62/595 (10.4%) were below the predicted 
limit of detection of DBS assays (Fig. 4C). 
4. Discussion 
In this study, we showed that the DBS based approach used is an 
insensitive approach relative to assays on venous plasma, with the limit 
of detection of the assay estimated to be about 30 times lower with DBS 
samples. This is not unexpected, because the DBS eluate is at best 10% 
plasma. In reality, elution will be incomplete, and (as we showed) 
smaller spots result in lower concentrations of antibody. Nevertheless, in 
the small sample tested, the sensitivity of DBS at our experimental cut- 
off relative to the reference test was 89%, with wide confidence intervals 
due to the small study size. This is compatible with an observation, in a 
much larger independent cohort of 595 seropositive individuals, that 
about 10% of the population studied have antibody concentrations 
which we estimate would not be detectable by DBS. 
This study has several important limitations. Firstly, DBS has only 
been tested on a relatively small sample set, only 18 of which were 
positive on the reference standard, and only four of whom had reported 
a previous PCR test and the majority of those testing positive reported 
Fig. 2. Dried blood spot collection kits. 
Figure 2 Images of dried blood spot collected on 
custom Perkin Elmer 226 collection card. The 4 
blood spots are removed from the collection 
card using disposable tweezers and eluted into a 
single eluate. (a) 25 μl dried blood spot: rated as 
“good”. DBS collected with spots smaller than 
those shown in the image were rated as small. 
(b) Image of “very small” dried blood spots 
collected on custom Perkin Elmer 226 collec-
tion card.   
Table 1 
Characteristics of the individuals eligible for DBS sampling (n=475)    
Sampled 
n = 195 
Not 
sampled 
n = 280 
Age 
18 to 24 9 (4.6%) 10 (3.6%) 
25 to 39 62 (32%) 96 (34%) 
40 to 59 115 
(59%) 
168 (60%) 
60+ 9 (4.9%) 6 (2.1%) 
Gender Male 
126 
(64%) 168 (60%) 









48 (25%) 50 (18%) 
Police 84 (43%) 125 (45%) 
Other 63 (32%) 105 (38%) 






Positive 18 (9%) 28 (10%)  
Fig. 3. Quality of DBS sample collected by each phlebotomist. 
Figure 3 The quality scores of blood spots achieved by each of seven 
phlebotomists. 
Table 2 







(95% CI)    
Pos Neg  
Manufacturer 
Positive Cut-off ≥ 
1.0 




100)  Neg 10 177  
Experimental 
Positive Cut-off ≥ 
0.17 
Pos 18 0 89.0 (67.2, 
96.9) 
100 (97.9, 
100) Neg 2 177 
DBS samples compared to matched plasma samples tested on the Roche Elecsys 
® Anti-SARS-CoV-2 immunassay. 
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having previously had COVID-19 compatible symptoms. Secondly, 
sensitivity and specificity estimates of the index test were based on cut- 
offs derived from the data, and so should be considered exploratory. 
Thirdly, we assessed samples taken by trained phlebotomist. Variation 
in performance was observed between phlebotomists (and presumably 
would also occur between self-taken samples); as such, usability studies 
to quantify the extent of this variation would be essential to understand 
how the tests perform when self-administered by the target population. 
In considering the generalisability of our study, the implications of 
the relative insensitivity of DBS approaches, and comparing our obser-
vations with those of others assessing DBS accuracy, there are some 
parallels with observations we made with another antibody detection 
technology (lateral flow testing) which is also insensitive relative to 
laboratory immunoassays [1]. In our recent work, we showed that the 
sensitivity of the lateral flow test appears higher if individuals with 
previous PCR positivity are examined (particularly those who had been 
eligible for testing at the start of the pandemic), because these people 
have more severe disease and higher antibody levels which are not 
representative of antibody levels in the general population, leading to a 
so called spectrum bias [23]. Comparisons of DBS accuracy using 
approaches using pre-pandemic samples vs. samples from individuals 
who are PCR positive may also overinflate estimates of DBS accuracy. 
Put alternatively, the analytical sensitivity of the test depends on the 
distribution of antibody concentrations in the target population; here, 
we used sequential sampling in a key worker population to try to obtain 
samples with an antibody distribution representative of that population, 
but we note that if other cohorts are studied in which antibody con-
centrations have declined compared with the one we studied, DBS will 
perform worse than we observe here. 
Our sampling strategy, used in an attempt to minimise spectrum bias 
[1], may explain the lower sensitivity we observed relative to (for 
example) the study by Karp et al, in which they observed a 100% 
sensitivity of DBS compared to plasma, however all their positive sam-
ples were taken in the spring and confirmed with PCR; as such, these 
individuals were more likely to have experienced more severe COVID-19 
(as testing was limited to these individuals at the time) and had limited 
time for antibody levels to decline [24]. Similar considerations apply 
when comparing our results with those of Morley et al, who report DBS 
analytical performance to be comparable to matched serum samples, 
with a sensitivity of 98.1% and specificity of 100%, when compared to 
Fig. 4. Immunoassay signals from plasma and 
DBS samples. 
Figure 4 (A) The relationship between antibody 
ratios obtained using Roche Elecsys immuno-
assays for plasma (reference text, x-axis) vs. 
paired dried blood spots (index test, y-axis). 
Samples positive in the plasma immunoassay 
are in red. Solid blue line: manufacturer’s cutoff 
for plasma samples (1). Red dotted line: exper-
imental cutoff ten median absolute deviations 
above the reference test negative median for 
DBS (index test) samples (n = 177). Blue dotted 
line: experimental cutoff ten median absolute 
deviations above the reference test negative 
median for plasma (reference test) samples. 
Solid black line: regression of index test 
immunoassay ratios on reference test immuno-
assay ratios. Arrow: estimate of limit of detec-
tion. (B) Receiver operator curve, showing 
sensitivity/specificity of DBS usage, relative to 
an immunoassay on plasma reference standard. 
(C) cumulative proportion of 595 seropositive 
cases from Police, Fire and Healthcare workers 
collected by EDSAB-HOME. There is no overlap 
with cases included in panel A. The estimated 
limit of sensitivity of the index test is shown as a 
dotted line.   
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an in-house ELISA which detects Spike glycoprotein antibodies [25]. 
None of these concerns preclude the use of DBS for sero-surveillance 
programs using the Roche Elecsys ® Nucleoprotein immunoassay, as 
long as the limits of detection (which will vary depending on elution 
efficiency and the dilution factor associated) are determined, verified 
and monitored and providedthe population antibody distribution is 
periodically monitored using plasma immunoassays to allow correction 
for DBS insensitivity. When considering large-scale DBS testing pro-
grammes, additional factors which might impact on programme success 
include the more complex processing of DBS samples relative to plasma 
samples upon arrival in the testing laboratory. However, this may not be 
a substantial barrier as options for automation have been presented by 
Gaugler et al [26]. 
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Table 3 
Demographics and clinical symptoms reported by individuals, stratified by DBS 










Age    
18 – 25 9 (4.6%) 2 (11.1%) 1 (6.2%) 
25 – 40 62 (31.8%) 6 (33.3%) 6 (37.5%) 
40 – 60 115 (59.0%) 10 (55.6%) 9 (56.2%) 
60+ 9 (4.6%) 0 (0.0%) 0 (0.0%)  
Sex    
Female 69 (35.4%) 8 (44.4%) 6 (37.5%) 
Male 126 (64.6%) 10 (55.6%) 10 (62.5%)  
Ethnicity    
White 181 (92.8%) 17 (94.4%) 16 (100.0%) 
Asian or British Asian 4 (2.1%) 0 (0.0%) 0 (0.0%) 
Black or Black British 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Mixed 8 (4.1%) 1 (5.6%) 0 (0.0%) 
Other 2 (1.0%) 0 (0.0%) 0 (0.0%)  
Do you think you have had 
previous COVID-19?    
Yes, I had symptoms but was 
not tested 
36 (18.5%) 8 (44.4%) 8 (50.0%) 
Yes, I had symptoms but my 
test(s) were all negative 
7 (3.6%) 1 (5.6%) 1 (6.2%) 
Yes, I had symptoms, and I had 
at least one positive test 
4 (2.1%) 4 (22.2%) 4 (25.0%) 
No 97 (49.7%) 1 (5.6%) 0 (0.0%) 
Unsure 51 (26.2%) 4 (22.2%) 3 (18.8%)  
Individual symptoms*    
Cough 30 (63.8%) 7 (53.8%) 7 (53.8%) 
Shortness of breath 27 (57.4%) 6 (46.2%) 6 (46.2%) 
Fever 26 (55.3%) 8 (61.5%) 8 (61.5%) 
Abnormal sense of smell 19 (40.4%) 12 (92.3%) 12 (92.3%) 
Abnormal sense of taste 19 (40.4%) 10 (76.9%) 10 (76.9%)  
Length of symptoms*    
Less than 7 days 18 (38.3%) 2 (15.4%) 2 (15.4%) 
7 -14 days 20 (42.6%) 8 (61.5%) 8 (61.5%) 
14 – 21 days 4 (8.5%) 1 (7.7%) 1 (7.7%) 
More than 21 days 5 (10.6%) 2 (15.4%) 2 (15.4%)  
Unable to work (in 
workplace or at home) 
due to symptoms*    
Yes 29 (61.7%) 10 (76.9%) 10 (76.9%) 
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